Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asciminib in CML-CP or CML-AP With T315I Mutation
NCT06514534Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Feb 2025
- Primary completion
- Feb 2029
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of asciminib in chronic myeloid leukemia (CML), sponsored by Novartis. Started Feb 2025; status: recruiting.
02
Drugs
asciminib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT06514534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06514534.